New drug cocktail aims to control advanced breast cancer
Disease control
Ongoing
This Phase 3 trial is testing a new drug called gedatolisib combined with fulvestrant, with or without palbociclib, in about 700 people with advanced HR+/HER2- breast cancer that has worsened after prior treatment. The goal is to see if this combination can slow cancer growth bet…
Phase: PHASE3 • Sponsor: Celcuity Inc • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC